Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

John T. Leith, Shaker A. Mousa, Aleck Hercbergs, Hung Yun Lin, Paul J. Davis

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T4), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T4 through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

Original languageEnglish
Pages (from-to)37069-37075
Number of pages7
JournalOncotarget
Volume9
Issue number97
Publication statusPublished - Dec 1 2018

Keywords

  • AKT
  • Epithelial-mesenchymal transition (EMT)
  • Integrin open configuration
  • L-thyroxine (T)
  • STAT3

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone'. Together they form a unique fingerprint.

  • Cite this

    Leith, J. T., Mousa, S. A., Hercbergs, A., Lin, H. Y., & Davis, P. J. (2018). Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone. Oncotarget, 9(97), 37069-37075.